Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 14/20 | 0.79 |
| ▸ | SYK | P43405 | 3/20 | 0.53 |
| ▸ | JAK1 | P23458 | 4/20 | 0.49 |
| ▸ | JAK3 | P52333 | 4/20 | 0.49 |
| ▸ | TYK2 | P29597 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | WEE1 | P30291 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778501 | 1.00 | KDR (0.79) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL1703631 | 0.88 | AURKB (1.00) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL3773560 | 0.88 | AURKB (1.00) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL3771697 | 0.88 | KDR (0.75) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL1703450 | 0.88 | KDR (0.75) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL1703907 | 0.86 | AURKB (1.00) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL3778135 | 0.86 | AURKB (1.00) | KDRAURKBSYKJAK1JAK3 | |
| SCHEMBL12565348 | 0.84 | SYK (0.58) | KDRAURKBSYKJAK2AURKA | |
| SCHEMBL12565351 | 0.82 | KDR (0.55) | KDRAURKBSYKJAK3TYK2 | |
| SCHEMBL3772761 | 0.82 | AURKB (1.00) | KDRAURKBSYKJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | claimed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | KDR 38/4885AURKB 3/4885SYK 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.